Extended Data Fig. 4: LPCAT1 is upregulated in RSL3-/erastin-resistant cells.
From: LPCAT1-mediated membrane phospholipid remodelling promotes ferroptosis evasion and tumour growth
a, Quantitative real-time (RT)-PCR analysis of expression of LPCAT1, ATRX, SPAG4, FGF2, MTMR11, S100A16, CD68, HSF4, TCIRG1, and UPP1 in the cells transfected with the corresponding siRNA. b, IB analysis of LPCAT1 expression in the indicated cells. GAPDH served as a loading control. c, Heatmaps showing the integration of FFA-alkyne into the membrane of the indicated cells. d, e, Scatter plots showing the changes in levels of phospholipids in the indicated cells vs. parental cells. FC, fold change. Cutoff: FC threshold = 2, P < 0.05. f–i, Repartition (left) and levels (right) of SFA, MUFA, and PUFA in phospholipids in the indicated cells. j, Representative images (left) and quantification (right) of membrane azide-fluor 488 fluorescence intensity in the indicated cells treated with PA-alkyne (5 μM, 10 h) or AA-alkyne (5 μM, 10 h) normalized against integrin β1 fluorescence intensity. Scale bar, 10 μm or 2 μm. Data are presented as mean ± SD, n = 3 biologically independent samples in a-i, n = 6 biologically independent samples in j. Statistical analysis was performed using an unpaired two-tailed Student’s t-test in d-i, one-way ANOVA followed by Dunnett’s test in a, j. NS, not significant.
